Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 558 | 2,673 | 1,249 | 420 | 2,935 |
| Other current assets | 1,064 | 820 | 6,914 | 1,555 | 968 |
| TOTAL | $1,893 | $4,451 | $8,944 | $2,683 | $4,774 |
| Non-Current Assets | |||||
| PPE Net | 64 | 77 | 88 | 86 | 75 |
| Other Non-Current Assets | 279 | 59 | 80 | 99 | 119 |
| TOTAL | $343 | $136 | $167 | $186 | $194 |
| Total Assets | $2,236 | $4,587 | $9,111 | $2,869 | $4,968 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | 1,848 | 2,005 | 1,840 |
| Accounts payable and accrued liabilities | 1,660 | 1,329 | 1,795 | 2,188 | 1,550 |
| Accrued Expenses | 914 | 793 | 658 | 444 | 350 |
| Other current liabilities | 7,177 | 7,165 | 7,724 | 1,110 | 1,146 |
| TOTAL | $9,817 | $9,368 | $12,119 | $6,146 | $5,237 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 209 | 0 | 0 | 8 | 32 |
| TOTAL | $209 | $N/A | $N/A | $8 | $32 |
| Total Liabilities | $10,025 | $9,368 | $12,119 | $6,154 | $5,269 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 3,886 | 3,886 | 3,886 | 3,649 | 1,984 |
| Common Shares | 972 | 972 | 4 | 496 | 496 |
| Retained earnings | -75,017 | -71,905 | -66,738 | -56,846 | -53,719 |
| TOTAL | $-7,789 | $-4,781 | $-3,008 | $-3,285 | $-302 |
| Total Liabilities And Equity | $2,236 | $4,587 | $9,111 | $2,869 | $4,968 |